NCT06351748Completed
Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)
Source: ClinicalTrials.gov · Last updated 16 Apr 2025
Brief summary (registry, in English)
This study is to describe the real-world use and impact of semaglutide once-weekly (OW) among participants with type 2 diabetes mellitus (T2DM) in China. Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List \[NRDL\] in China\] and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023) will be included in this study. The study period will be 36 months prior to the first date of participants identification period.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 34238 (actual)
- First submitted
- 2 Apr 2024
- Start date
- Jan 2024
- Primary completion date
- Mar 2024
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Type 2 diabetes
- NCT number
- NCT06351748
What you commit to
- Study type: Observational
- Participants enrolled: 34238
- From Jan 2024 to the primary completion date, Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants with diagnosis of type 1 diabetes prior to or on index date
- Participants who were pregnant within 36 months prior to or on index date
- Participants who participated in any clinical trials within 36 months prior to or on index date which could be identified from medical records
Who the study is looking for
- Male or female participants aged greater than or equal to (≥) 18 years on index date
- Participants with diagnosis of T2DM prior to or on index date
- Participants with initiation of semaglutide OW for the first time within the identification period
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tianjin Medical University Chu Hsien-I Memorial Hospital Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
Related publications
- Combined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis.Diabetes Ther · 2026 · PMID 42803912
- Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China.Diabetes Ther · 2026 · PMID 41848818
This page is information, not medical advice. Discuss any trial with your doctor.